Latest News & Features
Americas
Human embryos whose genomes have been edited should not be used to create a pregnancy until it is certain that changes can be made without introducing undesired changes, according to a new report by an influential panel. 10 September 2020
Americas
A US Department of Health and Human Services agency will investigate whether Moderna disclosed information on government funding in patent applications relating to its COVID-19 vaccine. 8 September 2020
Big Pharma
The US Federal Trade Commission has approved a final order regarding charges that biopharmaceutical company AbbVie’s $63 billion acquisition of Allergan would violate US federal antitrust law. 7 September 2020
Biotechnology
Biologics are playing an increasingly important role in healthcare, but for corporate patent counsel, the differences in rules between the US and Europe are a real cause for concern. 4 September 2020
Big Pharma
Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa. 4 September 2020
Generics
Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis. 3 September 2020
Americas
California-based molecular diagnostics company CareDx and Stanford University have dropped their patent infringement suit against Tai Diagnostics, nearly five months after filing the complaint. 3 September 2020
article
The pharmaceutical industry has continued to shift towards biologic-based drugs. Protecting the underlying technology continues to be a priority for companies and, indeed, patents covering these antibody drugs are worth billions of dollars. However, as the science and case law in this area have evolved, biopharmaceutical companies now face even higher hurdles on the road to the effective protection of their innovations. 3 September 2020
article
The pharmaceutical industry has continued to shift towards biologic-based drugs. Protecting the underlying technology continues to be a priority for companies and, indeed, patents covering these antibody drugs are worth billions of dollars. However, as the science and case law in this area have evolved, biopharmaceutical companies now face even higher hurdles on the road to the effective protection of their innovations. 3 September 2020
Big Pharma
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells. 2 September 2020